Fig 1.
Iodine contrast agent used to identify mouse prostate.
Organically bound iodine was directly injected into the prostate of a recently deceased mouse. A CT demonstrating high contrast between the prostate tissue and surrounding soft tissues. Purple arrows indicate the prostate in each view. Yellow arrows indicate the bladder in views where it is in plane. (n = 1).
Fig 2.
CT image of a normal mouse prostate and adjacent organs without image contrast agent.
A non-contrast CT scan of a live mouse with a normal sized prostate. A. CT with labeled pelvic anatomy. The crosshairs are centered on the bladder. From the bottom left image, transverse view, the bladder (yellow) is above the prostate (red) and seminal vesicles (green), and below those structures is the colon (blue). B. Transverse view of the pelvis. The red line shows the transverse prostate boundaries. C. Sagittal view of the prostate. The red line shows the sagittal prostate boundaries. (This data is representative of 9 mice).
Fig 3.
RM-1 tumor growth measured with CT as compared to ex vivo measurement.
RM-1 tumors were orthotopically implanted into C57Bl/6J mice and allowed to grow for three weeks. A. Tumor growth measured by CT imaging weekly until 46 days post-implantation. B. The tumors were removed and measured ex vivo with calipers for comparison to the final CT calculated volume. C. Comparison of estimated tumor volume in CT and ex vivo caliper tumor measurement at 46 days implantation, n = 9 mice.
Fig 4.
LNCaP orthotopic tumor growth estimated with bioluminescence or CT.
LNCaP tumors growing in NU/J mice were measured with A IVIS or B CT. C Each graph represents a different mouse. Comparing the growth curves generated from the two imaging techniques, in several animals, it is common to observe typical exponential growth in the CT imaged tumors and abnormal increases and decreases in the IVIS generated growth curves, n = 20 mice.
Fig 5.
CT imaging more closely reflects ex vivo tumor size as compared to bioluminescence imaging.
LNCaP prostate tumors at 8 weeks post-implantation. A Bioluminescent imaging used to measure orthotopic prostate tumors. B CT imaging used to measure the same orthotopic prostate tumor. C. Excised tumors measured with calipers for comparison at this 8-week time point, n = 5 mice.
Fig 6.
CT imaging significantly correlates with ex vivo tumor measurements.
LNCaP tumors were removed at 8, 10-and 12 weeks post-implantation immediately following imaging. A. CT and IVIS bioluminescence imaging show no significant correlation to one another. B. CT and ex vivo tumor measurements are significantly correlated. C. IVIS bioluminescence imaging and ex vivo measurements have no significant correlation, n = 15 mice.